Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...

What is the AVISE® CTD? AVISE® CTD is a blood test that can help doctors diagnose lupus and other autoimmune diseases — like rheumatoid arthritis, Sjögren's syndrome, or scleroderma. The test may be ...

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (XGN), a leading provider of autoimmune testing, today announced the completion of its 1,000,000 th AVISE CTD test, marking a ...

“The addition of these biomarkers to the AVISE CTD test is an important milestone for those of us working with suspected autoimmune patients,” said Vasileios Kyttaris, MD, PhD, FACR. “We as clinicians ...

Exagen (XGN) announced the completion of its 1,000,000th AVISE CTD test, marking a significant milestone that underscores the company’s dedication to supporting patients and clinicians managing ...

The European Alliance of Associations for Rheumatology – has worked with the European Respiratory Society (ERS) to develop new clinical practice guidelines for interstitial lung disease (ILD) ...

- Revenue (GAAP) rose to $17.2 million, surpassing analyst expectations by 5.5% and grew 14.2% year over year. - AVISE CTD test volume increased 14% sequentially, and the trailing-twelve-month average ...

John Aballi, CEO, stated that "Q2 revenue came in at $17.2 million, representing 14% year-over-year growth and the highest quarterly revenue in company history." He highlighted substantial AVISE CTD ...